<DOC>
	<DOCNO>NCT00968864</DOCNO>
	<brief_summary>The primary purpose determine ability CD34+ selection T cell depletion use CliniMACS® device prevent severe acute graft-versus-host disease ( GVHD ) patient receive stem cell transplant alternative ( unrelated mismatch relate ) donor . The secondary objective include evaluation engraftment , immune recovery , post-transplant infection . Patients require stem cell transplant either malignant ( cancerous ) non-malignant disease include study . The recipient group one two group base whether donor mismatch relate ( Cohort A ) unrelated ( Cohort B ) . The patient receive condition regimen include chemotherapy drug and/or total body irradiation base disease transplant perform .</brief_summary>
	<brief_title>T-cell Depleted Alternative Donor Transplantation</brief_title>
	<detailed_description>A major issue alternative donor ( mismatch relate unrelated donor transplantation development graft-versus-host disease ( GVHD ) . Several clinical trial show use T-cell deplete peripheral blood stem cell ( PBSC ) reduce GVHD alternative donor transplant . The purpose study determine ability CD34 positive selection T cell depletion use CliniMACS® Device GVHD prophylaxis prevent severe acute GVHD recipient alternative donor PBSC transplant . Mismatched related donor match least 3 6 Human leukocyte antigen ( HLA ) ( haplocompatible ) unrelated donor match least 6 8 HLA antigen transplant recipient . The conditioning therapy include chemotherapy , anti-thymocyte globulin ( ATG ) , +/- total body irradiation ( TBI ) base patient 's diagnosis . The transplant recipient follow 5 year transplant GVHD , engraftment , post-transplant infection , disease relapse , overall survival . In addition , study serve platform companion study therapy accelerate immune recovery transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Osteopetrosis</mesh_term>
	<criteria>Age &lt; 30 year Patient must malignant nonmalignant disease benefit alternative stem cell transplantation . Examples include acute chronic leukemia , myelodysplastic syndrome , lymphoma , severe acquire congenital cytopenia , white red blood cell abnormality , immunodeficiency . Patients acute lymphoblastic leukemia must morphological remission ( &lt; 5 % blast ) time transplant . Patients acute nonlymphocytic leukemia preferably morphologic remission may enrol aplastic chemotherapy &lt; 20 % blast . Patients lymphoma must complete close complete remission ( residual adenopathy , PET scan must negative slight uptake , eg . SUV &lt; 2 ) . Patients must lack healthy HLAidentical relate donor least one year age . Patient must mismatch related unrelated donor : 1 . Able receive GCSF undergo apheresis either placement catheter antecubital vein temporary central venous catheter , 2 . Healthy , 3 . Willing , 4 . For recipient unrelated donor transplant , recipient eligibility restrict follow judgment recipient ' transplant physician , recipient receive transplant combine positive negative fraction describe Section 6.1.3.2 unmanipulated PBSC product . 5 . Meets eligibility criterion donor . If one mismatch related relative available , acceptable unrelated donor must identify backup . Patient authorize guardian must sign informed consent study . Patient anticipate life expectancy &lt; 1 month Active infectious hepatitis CMV infection HIV HTLVI/II infection Serious infection ( bacterial , fungal , viral ) within last 4 week Cardiac ejection fraction &lt; 45 % ; low patient clinical cardiac failure reduce intensity condition regimen use . Creatinine clearance &lt; 60 ml/min/1.72 m2 ; low reduce intensity condition regimen use . Pulmonary diffusion capacity ( adjust Hgb ) , FEV1 , FVC &lt; 60 % predict O2 sit &lt; 94 % unable perform PFTs ; low reduce intensity condition regimen use . Serum ALT &gt; 3 x upper limit normal ( 5 x upper limit normal reduce intensity condition regimen use ) bilirubin &gt; 2 . The bilirubin criterion sickle cell disease patient direct bilirubin &gt; 2x upper limit normal . Performance score ( Lansky/Karnofsky ) &lt; 50 Any condition compromise compliance procedure protocol , judge principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>T cell deplete</keyword>
	<keyword>Matched unrelated donor</keyword>
	<keyword>Haplocompatible donor</keyword>
</DOC>